CTIS2024-516338-37-00进行中（未招募）1 期
STX-102
SentryX B.V.0 个研究点目标入组 12 人开始时间: 2024年8月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors.Advanced solid tumors including but not limited to gynecologic CancerHead and Neck Squamous Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10041823Term: Squamous cell carcinoma Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10014733Term: Endometrial cancer Class: 100000004864Breast CancerCTIS2023-504807-94-00Scorpion Therapeutics Inc.220
招募中
1 期
A study of STX-721 in participants with non-small cell lung cancer with certain mutationsocally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: LLTClassification code: 10029514Term: Non-small cell lung cancer NOS Class: 10029104CTIS2023-506759-51-00Scorpion Therapeutics Inc.112
招募中
1 期
A Phase 1/2 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Relapsed/Refractory B Cell and T-Cell LymphomasRelapsed/refractory (R/R) B-cell and T-cell lymphomasMedDRA version: 20.0Level: PTClassification code: 10003899Term: B-cell lymphoma Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10042971Term: T-cell lymphoma Class: 100000004864CTIS2022-502299-21-00Step Pharma189
招募中
1 期
A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumoursocally advanced or metastatic solid tumorsMedDRA version: 21.1Level: PTClassification code: 10028997Term: Neoplasm malignant Class: 100000004864CTIS2023-508764-30-00Chugai Pharmaceutical Co. Ltd.150
招募中
1 期
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)Breast CancerCTIS2022-503114-23-00Stemline Therapeutics Inc.640